Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8716812 | 0.88 | RPS6KA3 (0.65) | RPS6KA3CYP3A4PRKCZCYP1A2CYP2E1 | |
| SCHEMBL21692148 | 0.83 | RPS6KA3 (0.59) | RPS6KA3CYP3A4PRKCZCYP1A2CYP2E1 | |
| SCHEMBL21692174 | 0.83 | RPS6KA3 (0.59) | RPS6KA3CYP3A4PRKCZCYP1A2CYP2E1 | |
| SCHEMBL18449559 | 0.83 | RPS6KA3 (0.53) | RPS6KA3PRKCZSLC22A12TDO2ALDH1A1 | |
| SCHEMBL18447769 | 0.83 | RPS6KA3 (0.53) | RPS6KA3PRKCZSLC22A12TDO2ALDH1A1 | |
| SCHEMBL28114956 | 0.80 | RPS6KA3 (0.62) | RPS6KA3CYP3A4HSD17B10CYP1A2CYP2E1 | |
| SCHEMBL12854064 | 0.79 | RPS6KA3 (0.56) | RPS6KA3CYP3A4PRKCZCYP1A2CYP2E1 | |
| SCHEMBL12854062 | 0.79 | RPS6KA3 (0.56) | RPS6KA3CYP3A4PRKCZCYP1A2CYP2E1 | |
| SCHEMBL9217300 | 0.79 | HSD17B10 (0.74) | CYP3A4HSD17B10TAAR1TDP1PRKCZ | |
| SCHEMBL10273187 | 0.79 | CYP17A1 (0.59) | RPS6KA3CYP3A4PRKCZCYP1A2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | RPS6KA3 1166/4885CYP3A4 27/4885HSD17B10 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.